Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Gambles Priority Review Voucher On Ilaris Gout Indication

You may also be interested in...



Priority Review Vouchers: Does Novartis Have User's Regret?

Stakeholders are sympathetic to FDA's concerns that voucher program requires diversion of precious resources, but some believe it provides substantial drug development incentive, particularly for small companies.

J&J’s Bedaquiline Advisory Cmte. Could Test Strength Of Phase II Argument For Tuberulosis Drugs

FDA’s Anti-Infective Drugs Advisory Committee will review J&J’s product, a diarylquinolone, for the treatment of multi-drug resistant pulmonary tuberculosis on Nov. 28.

R&D For Diseases Of Developing Countries Could Be Driven By Pooled Funds

WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.

Related Content

Topics

UsernamePublicRestriction

Register

PS053537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel